Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer

International Journal of Clinical Oncology

Volumn 18, Issue 4, 2013, Pages 735-742

  Sasaki, Tetsuya ^a,b   Fujita, Ken Ichi ^a   Sunakawa, Yu ^a   Ishida, Hiroo ^a,c   Yamashita, Keishi ^a   Miwa, Keisuke ^a   Saji, Shigehira ^a,d   Kato, Yasuhisa ^b   Sasaki, Yasutsuna ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Adverse drug reactions; Cancer; Clinical practice; Concomitant medications; Irinotecan

Indexed keywords

ATENOLOL; ATORVASTATIN; AZELNIDIPINE; BENAZEPRIL; BISOPROLOL; CARVEDILOL; DIGOXIN; DOXAZOSIN; ENALAPRIL; FLUOROURACIL; FOLINIC ACID; FUROSEMIDE; IMIDAPRIL; IRINOTECAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; METILDIGOXIN; METOPROLOL; NITRENDIPINE; OLMESARTAN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; TEMOCAPRIL; TRANEXAMIC ACID; TRICHLORMETHIAZIDE; TRIPAMIDE; UNINDEXED DRUG; VALSARTAN;

ADULT; AGED; ARTICLE; COMORBIDITY; DIARRHEA; FEMALE; HUMAN; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUTROPENIA; POLYPHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DIARRHEA; FEMALE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HUMANS; LEUCOVORIN; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; POLYPHARMACY; RETROSPECTIVE STUDIES;

EID: 84882595334     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0425-5     Document Type: Article

References (22)

1. Beijnen JH, Schellens JH (2004) Drug interactions in oncology. Lancet Oncol 5:489-496
2. Blower P, de Wit R, Goodin S et al (2005) Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 55:117-142
3. Chan A, Yap KY, Koh D et al (2011) Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians. Pharmacoepidemiol Drug Saf 20:939-947
4. Jansman FG, Idzinga FS, Smit WM et al (2005) Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Clin Ther 27:327-335
5. Jansman FG, Reyners AK, van Roon EN et al (2011) Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther 33:305-314
6. Riechelmann RP, Tannock IF, Wang L et al (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592-600
7. Kudoh S, Fujiwara Y, Takada Y et al (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16:1068-1074
8. Negoro S, Fukuoka M, Masuda N et al (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168
9. Rougier P, Van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412
10. Fujita K, Sasaki Y (2007) Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab 8:554-562
11. Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926
12. Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388
13. Araki K, Fujita K, Ando Y et al (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255-1259
14. Han JY, Lim HS, Shin ES et al (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237-2244
15. Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and*28. Pharmacogenet Genomics 17:497-504
16. Brunton LL, Lazo JS, Parker KL (2006) Goodman & Gilman's the pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York
17. Corcoran ME (1997) Polypharmacy in the older patient with cancer. Cancer Control 4:419-428
18. Yancik R (1997) Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 80:1273-1283
19. Oda M, Kotegawa T, Tsutsumi K et al (2003) The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol 59:615-619
20. Araki K, Yasui-Furukori N, Fukasawa T et al (2004) Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 60:427-430
21. Sparreboom A, Fujita K, Zamboni WC (2010) Topoisomerase I-targeting drugs. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 342-355
22. de Jong FA, van der Bol JM, Mathijssen RH et al (2008) Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 84:254-262